Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease

被引：0
|
作者：
Tang, Mengyao [1 ,2 ]
Morieri, Mario Luca [3 ]
Kalim, Sahir [1 ,2 ]
Doria, Alessandro [2 ,4 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA USA
[2] Harvard Med Sch, Dept Med, Boston, MA USA
[3] Univ Padua, Dept Med, Padua, Italy
[4] Joslin Diabet Ctr, Res Div, Boston, MA 02215 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2025年
关键词：
diabetic kidney disease;
D O I：
10.1681/ASN.0000000620
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation
    Rroji, Merita
    Spahia, Nereida
    Figurek, Andreja
    Spasovski, Goce
    BIOMEDICINES, 2025, 13 (03)
  • [32] GLP-1 receptor agonists in comparison with SGLT-2 inhibitors
    Pavlicek, Vojtech
    DIABETOLOGE, 2020, 16 (05): : 530 - 531
  • [33] Impact of GLP-1 receptor agonists versus SGLT-2 inhibitors on diabetic retinopathy
    Joo, Julia
    Sharma, Neha
    Daugirdas, Sarunas
    Wu, Anna K.
    Russell, Matthew W.
    Skugor, Mario
    Singh, Rishi
    Rachitskaya, Aleksandra V.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [34] Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
    Sawami, Kosuke
    Tanaka, Atsushi
    Node, Koichi
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [35] Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
    Munir, Kashif M.
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (08) : 773 - 777
  • [36] Positioning of GLP-1 receptor agonists and SGLT2 inhibitors: what do the guidelines say in diabetes?
    Darmon, P.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2023, 27 (02): : 62 - 65
  • [37] A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
    Consoli, Agostino
    Formoso, Gloria
    Baldassarre, Maria Pompea Antonia
    Febo, Fabrizio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (03) : 293 - 302
  • [38] GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors
    Patel, Rushin
    Wadid, Mark
    Makwana, Bhargav
    Kumar, Ashish
    Khadke, Sumanth
    Bhatti, Ammar
    Banker, Ahan
    Husami, Zaid
    Labib, Sherif
    Venesy, David
    Fonarow, Gregg
    Kosiborod, Mikhail
    Al-Kindi, Sadeer
    Bhatt, Deepak L.
    Dani, Sourbha
    Nohria, Anju
    Butler, Javed
    Ganatra, Sarju
    JACC-HEART FAILURE, 2024, 12 (11) : 1814 - 1826
  • [39] Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
    Puglisi, Soraya
    Rossini, Alessandro
    Poli, Roberta
    Dughera, Francesca
    Pia, Anna
    Terzolo, Massimo
    Reimondo, Giuseppe
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [40] Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on risk of diabetic eye complications
    Tsai, Yi-Hsuan
    Hemphill, Nefertiti OjiNjideka
    Kurth, Tobias
    DIABETOLOGIA, 2025, 68 (01) : 247 - 248
12345